Gossamer Bio Inc (GOSS)

$0.806

-0.01

(-1.71%)

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Gossamer Bio Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 48.8% return, outperforming this stock by 69.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 237.7% return, outperforming this stock by 328.1%

Performance

  • $0.79
    $0.86
    $0.81
    downward going graph

    2.46%

    Downside

    Day's Volatility :7.87%

    Upside

    5.55%

    downward going graph
  • $0.45
    $1.88
    $0.81
    downward going graph

    44.14%

    Downside

    52 Weeks Volatility :75.93%

    Upside

    56.91%

    downward going graph

Returns

PeriodGossamer Bio IncSector (Health Care)Index (Russel 2000)
3 Months
-7.36%
-0.7%
0.0%
6 Months
43.93%
7.7%
0.0%
1 Year
-20.2%
3.3%
-1.7%
3 Years
-90.37%
13.9%
-20.7%

Highlights

Market Capitalization
181.8M
Book Value
$0.28
Earnings Per Share (EPS)
-1.18
Wall Street Target Price
5.72
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-37.17%
Return On Equity TTM
-480.5%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-172.2M
Diluted Eps TTM
-1.18
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.76
EPS Estimate Next Year
-0.7
EPS Estimate Current Quarter
-0.21
EPS Estimate Next Quarter
-0.19

Analyst Recommendation

Buy
    64%Buy
    29%Hold
    5%Sell
Based on 17 Wall street analysts offering stock ratings for Gossamer Bio Inc(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
12
Hold
5
5
5
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 609.68%

Current $0.81
Target $5.72

Technicals Summary

Sell

Neutral

Buy

Gossamer Bio Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Gossamer Bio Inc
Gossamer Bio Inc
-42.01%
43.93%
-20.2%
-90.37%
-95.13%
Moderna, Inc.
Moderna, Inc.
-2.96%
23.83%
-28.58%
-37.0%
331.65%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.23%
10.55%
10.52%
78.91%
167.64%
Novo Nordisk A/s
Novo Nordisk A/s
-6.56%
25.69%
48.76%
237.69%
410.4%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-5.23%
7.86%
19.8%
79.52%
133.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Gossamer Bio Inc
Gossamer Bio Inc
NA
NA
NA
-0.76
-4.8
-0.37
NA
0.28
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.8
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.3
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Gossamer Bio Inc
Gossamer Bio Inc
Buy
$181.8M
-95.13%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$39.1B
331.65%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
167.64%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
410.4%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.49%
28.42
36.68%

Institutional Holdings

  • NEA Management Company, LLC

    7.02%
  • FMR Inc

    5.44%
  • Artal Group S A

    5.35%
  • Vanguard Group Inc

    5.16%
  • EcoR1 Capital, LLC

    4.08%
  • Octagon Capital Advisors LP

    3.63%

Corporate Announcements

  • Gossamer Bio Inc Earnings

    Gossamer Bio Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

gossamer bio is a san diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. founded by the former receptos executive team, gossamer bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.

Organization
Gossamer Bio Inc
Employees
135
CEO
Mr. Faheem Hasnain
Industry
Pharmaceuticals: Major

FAQs